{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-023538","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2026-07-14T20:21:27+00:00","discovered_at":"2026-07-14T20:22:02.339674+00:00","generated_at":"2026-07-14T20:22:11.719820+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CervoMed presents new neflamapimod data at AAIC 2026; supports Phase 3 dose 50 mg TID in DLB","bullets":["New analyses from Phase 2b RewinD-LB show neflamapimod slowed worsening in DLB patients with low pTau181 and adequate drug exposure.","Neflamapimod produced durable slowing of basal forebrain atrophy over 48 weeks and increased basal forebrain connectivity vs placebo.","Phase 2 study of 80 mg BID met primary safety, tolerability, and PK objectives; encouraging secondary clinical activity findings.","PK-PD analysis identifies plasma trough threshold ~4 ng/mL; 50 mg TID dose expected to achieve threshold in ~90% of patients.","Company gained alignment with FDA, EMA, MHRA, and PMDA for planned Phase 3 trial in DLB."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-023538","json":"https://secwatch.observer/filing/0001437749-26-023538.json","markdown":"https://secwatch.observer/filing/0001437749-26-023538.md","text":"https://secwatch.observer/filing/0001437749-26-023538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926023538/0001437749-26-023538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926023538/crvo20260714_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-14T20:22:11.719820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}